{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:14:37Z","timestamp":1757618077009,"version":"3.44.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["No. 7232137"],"award-info":[{"award-number":["No. 7232137"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["No.2024-I2M-C&T-A-009"],"award-info":[{"award-number":["No.2024-I2M-C&T-A-009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06430-x","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T20:12:24Z","timestamp":1748895144000},"page":"3423-3431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term follow-up of autologous hematopoietic cell transplantation for diffuse large B cell lymphoma in the rituximab era: real\u2011world data from a retrospective single\u2011center analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Jiangtao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiefei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"6430_CR1","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R et al (2018) Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med 378:1396\u20131407","journal-title":"N Engl J Med"},{"key":"6430_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679\u2013690","journal-title":"Nat Med"},{"key":"6430_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-Cell lymphoma. N Engl J Med 384:842\u2013858","journal-title":"N Engl J Med"},{"key":"6430_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","volume":"29","author":"N Epperla","year":"2023","unstructured":"Epperla N et al (2023) ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma. Transpl Cell Ther 29:548\u2013555","journal-title":"Transpl Cell Ther"},{"key":"6430_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-024-01085-9","volume":"14","author":"P Berning","year":"2024","unstructured":"Berning P et al (2024) Hematopoietic stem cell transplantation for DLBCL: a report from the European society for blood and marrow transplantation on more than 40,000 patients over 32 years. Blood Cancer J 14:106","journal-title":"Blood Cancer J"},{"key":"6430_CR6","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ et al (2017) Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med 377:2545\u20132554","journal-title":"N Engl J Med"},{"key":"6430_CR7","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/bjh.19860","volume":"205","author":"IE Karsten","year":"2024","unstructured":"Karsten IE, Shumilov E, Schmitz N, Lenz G (2024) Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs. Br J Haematol 205:2163\u20132174","journal-title":"Br J Haematol"},{"key":"6430_CR8","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s00277-021-04650-5","volume":"100","author":"R Wullenkord","year":"2021","unstructured":"Wullenkord R et al (2021) The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Ann Hematol 100:2733\u20132744","journal-title":"Ann Hematol"},{"key":"6430_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40164-019-0131-3","volume":"8","author":"M Carlsten","year":"2019","unstructured":"Carlsten M et al (2019) The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994\u20132016. Exp Hematol Oncol 8:7","journal-title":"Exp Hematol Oncol"},{"key":"6430_CR10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"6430_CR11","doi-asserted-by":"publisher","first-page":"32e1","DOI":"10.1016\/j.jtct.2021.10.010","volume":"28","author":"RW Merryman","year":"2022","unstructured":"Merryman RW et al (2022) Immune reconstitution following High-Dose chemotherapy and autologous stem cell transplantation with or without pembrolizumab maintenance therapy in patients with lymphoma. Transpl Cell Ther 28:32e1\u201332e10","journal-title":"Transpl Cell Ther"},{"key":"6430_CR12","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ajh.25826","volume":"95","author":"E Maffini","year":"2020","unstructured":"Maffini E et al (2020) CD34\u2009+\u2009cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working party of the European society for blood and marrow transplantation (EBMT). Am J Hematol 95:892\u2013899","journal-title":"Am J Hematol"},{"key":"6430_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","volume":"100","author":"M Christopeit","year":"2021","unstructured":"Christopeit M et al (2021) Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous Haematopoietic stem cell transplantation. 2020 update of the recommendations of the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO). Ann Hematol 100:321\u2013336","journal-title":"Ann Hematol"},{"key":"6430_CR14","doi-asserted-by":"crossref","unstructured":"Wahren-Herlenius M, D\u00f6rner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382, 819\u2013\u200931","DOI":"10.1016\/S0140-6736(13)60954-X"},{"key":"6430_CR15","doi-asserted-by":"crossref","unstructured":"Puckrin R et al (2023) Consolidative Autotransplantation Achieves High Cure Rates in Adverse-Risk Large B Cell Lymphoma. Transplant Cell Ther 29, 763.e1-763.e5","DOI":"10.1016\/j.jtct.2023.09.005"},{"key":"6430_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jtct.2022.06.015","volume":"28","author":"AM Tun","year":"2022","unstructured":"Tun AM et al (2022) Progression-Free survival at 24 months as A landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma. Transpl Cell Ther 28:610\u2013617","journal-title":"Transpl Cell Ther"},{"key":"6430_CR17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.bbmt.2008.05.002","volume":"14","author":"TM Wildes","year":"2008","unstructured":"Wildes TM et al (2008) Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transpl 14:840\u2013846","journal-title":"Biol Blood Marrow Transpl"},{"key":"6430_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/annonc\/mdr035","volume":"23","author":"E Jantunen","year":"2012","unstructured":"Jantunen E et al (2012) Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European group for blood and marrow transplantation (EBMT). Ann Oncol 23:166\u2013171","journal-title":"Ann Oncol"},{"key":"6430_CR19","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1097\/CM9.0000000000002940","volume":"137","author":"H Zou","year":"2024","unstructured":"Zou H et al (2024) Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features. Chin Med J (Engl) 137:1620\u20131622","journal-title":"Chin Med J (Engl)"},{"key":"6430_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s12032-011-0029-3","volume":"29","author":"JS Ungerstedt","year":"2012","unstructured":"Ungerstedt JS et al (2012) Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. Med Oncol 29:2191\u20132199","journal-title":"Med Oncol"},{"key":"6430_CR21","first-page":"2186","volume":"109","author":"AM Tun","year":"2024","unstructured":"Tun AM et al (2024) Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica 109:2186\u20132195","journal-title":"Haematologica"},{"key":"6430_CR22","doi-asserted-by":"publisher","first-page":"1432310","DOI":"10.3389\/fonc.2024.1432310","volume":"14","author":"JM Heger","year":"2024","unstructured":"Heger JM et al (2024) Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019. Front Oncol 14:1432310","journal-title":"Front Oncol"},{"key":"6430_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/17474086.2016.1180972","volume":"9","author":"JL Koff","year":"2016","unstructured":"Koff JL, Flowers CR (2016) B cells gone Rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease. Expert Rev Hematol 9:553\u2013561","journal-title":"Expert Rev Hematol"},{"key":"6430_CR24","doi-asserted-by":"crossref","unstructured":"Morton LM et al (2014) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014, 130\u2013\u200944","DOI":"10.1093\/jncimonographs\/lgu013"},{"key":"6430_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","volume":"24","author":"E Baecklund","year":"2014","unstructured":"Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R (2014) Lymphoma development in patients with autoimmune and inflammatory disorders\u2013what are the driving forces? Semin Cancer Biol 24:61\u201370","journal-title":"Semin Cancer Biol"},{"key":"6430_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-018-0105-4","volume":"8","author":"G Kleinstern","year":"2018","unstructured":"Kleinstern G et al (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73","journal-title":"Blood Cancer J"},{"key":"6430_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/hon.2498","volume":"36","author":"G Kleinstern","year":"2018","unstructured":"Kleinstern G et al (2018) Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma. Hematol Oncol 36:457\u2013462","journal-title":"Hematol Oncol"},{"key":"6430_CR28","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1002\/ijc.27944","volume":"132","author":"JF Simard","year":"2013","unstructured":"Simard JF et al (2013) Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes. Int J Cancer 132:2659\u20132666","journal-title":"Int J Cancer"},{"key":"6430_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00277-018-3515-2","volume":"98","author":"S Hu","year":"2019","unstructured":"Hu S et al (2019) Autoimmune disease-associated non-Hodgkin\u2019s lymphoma-a large retrospective study from China. Ann Hematol 98:445\u2013455","journal-title":"Ann Hematol"},{"key":"6430_CR30","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","volume":"369","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ et al (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 369:1681\u20131690","journal-title":"N Engl J Med"},{"key":"6430_CR31","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","volume":"18","author":"A Chiappella","year":"2017","unstructured":"Chiappella A et al (2017) Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol 18:1076\u20131088","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06430-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:24:37Z","timestamp":1757179477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06430-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6430"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06430-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}